CHICAGO—Men who had breast-conserving therapy (BCT) including radiation for their early breast cancer lived longer than those who had total or partial mastectomy—with or without radiation—in findings from a large retrospective survey of male breast cancer reported at the 2018 Annual Meeting of the American Society of Clinical Oncology (ASCO).
In a poster presentation at ASCO Sarah Bateni MD, a surgery resident at the University of California Davis Medical Center in Sacramento, reported survival outcomes from an analysis of National Cancer Database (NCDB) records of 11,406 men who had stage one, two or three breast cancer between the years 2004 and 2015. She discusses the findings with the Audio Journal of Oncology in the company of her colleague, Candice A. M. Sauder, MD, MEd, a Breast Surgical Oncologist at University of California Davis Medical Center.
Sarah Bateni & Candice Sauder AJO
CHICAGO—A “cluster randomized controlled trial” of treatment for patients with advanced cancers found that the use of standardized geriatric assessments significantly increased the number and quality of discussions about age-related concerns in comparison with usual care and also resulted in higher scores of patient satisfaction—which the investigators regarded as paramount among therapy outcomes. (https://meetinglibrary.asco.org/record/159519/abstract)
In a media briefing about the study held at the 2018 Annual Meeting of the American Society of Clinical Oncology lead author Supriya Gupta Mohile MD MS, the Wehrheim professor of medicine and surgery and director of geriatric oncology at the University of Rochester, New York, emphasized the pivotal role of GA when treating older patients for their late-stage cancers. She talks with the Audio Journal of Oncology.
Supriya Gupta Mohile AJO INTERVIEW Production MASTER
CHICAGO—Women and men were treated differently for the same tumor stages of head and neck cancer (HNC) and had different outcomes in a study with patients surveyed over a fifteen-year period in Santa Clara, California. The findings—using the generalized competing event (GCE) assessment model that balanced the risk of cancer death against non-cancer death—has prompted a call to reassess the influence of gender on treatment decision-making.
Study author Jed A. Katzel MD, a medical oncologist with Kaiser Permanente in Santa Clara, talks with the Audio Journal of Onclogy about his new data from GCE modeling he reported at the 2018 annual meeting of the American Society of Clinical Oncology (ASCO).
(Abstract LBA6002: Are women with head and neck cancer undertreated?)
Commenting on the findings ASCO Expert Joshua A Jones, MD MA, a radiation oncologist at the Perelman School of Medicine at University of Pennsylvania in Philadelphia said: “We don’t know why women are getting less treatment and having worse outcomes and we need to find out. Though these findings are specific to California the disparities we see are startling and worth considering in treatment discussions in everyday practice.”
Jed Katzel AJO PRODUCTION MASTER
CHICAGO, IL—Patients whose non-small cell lung cancers (NSCLC) expressed more than one per cent of the programmed death ligand-1 (PD-L1) tumor proportion score (TPS) lived longer when treated with the anti programmed death 1 (PD-1) antibody pembrolizumab than a control group of patients receiving platinum-based chemotherapy in the open-label, phase three KEYNOTE-042 study reported at the American Society of Clinical Oncology (ASCO) annual meeting plenary session. https://meetinglibrary.asco.org/record/165950/abstract
Principal author of the study, Gilberto Lopes MD, Associate Professor of Clinical Medicine at the University of Miami’s Sylvester Comprehensive Cancer Center tells the Audio Journal of Onclogy patients treated with pebrolizumab monotherapy lived a median of four to eight months longer than those who received chemotherapy and had fewer severe side effects than with chemotherapy (18 per cent as compared with 41 per cent).
CHICAGO—Prophylactic contralateral (CLT) breast radiotherapy was associated with significantly fewer and delayed cases of breast cancer in women having standard therapy for their ipsilateral BRCA mutation-associated breast cancers in a study from Israel reported in a poster session at the American Society of Clinical Oncology 2018 annual meeting.
(Phase II national clinical trial of prophylactic irradiation to the contralateral breast for BRCA mutation carriers treated for early breast cancer.)
Jewish women, high risk
Ella Evron MD, a medical oncologist at the Kaplan hospital in Zerifin, Israel, said that in Israel they saw many patients with BRCA-associated breast cancer because three “founder mutations” are commonly detected in Ashkenazi Jews who are at very high risk of developing breast cancer. She tells the Audio Journal of Oncology about the opportunity to study prophylactic radiotherapy because women increased risk of getting contralateral breast cancer were declining prophylactic surgery because of the fear of its impact on their lives.Ella Evron PRODUCTION MASTER for AJO
BARCELONA—Handgrip strength (HGS) was found to be an independent quantitative marker for overall survival among patients with early-stage non-small cell lung cancer (NSCLC) being treated with stereotactic body radiotherapy (SBRT) in a study discussed at the 2018 European Society for Radiotherapy & Oncology (ESTRO 37) conference.
ABSTRACT: PV-0041 Hand grip strength: independent prognostic selection test for OS in stage I NSCLC treated with SBRT
The investigators used a handgrip strength test before patients were treated with SBRT and followed them up for survival. First author Stéphanie Peeters MD PhD, a radiation oncologist from the MAASTRO Clinic in Maastricht, Netherlands tells the Audio Journal of Onclogy how they saw that there was indeed a correlation between a weak handgrip strength and overall survival and only 12 per cent of patients with handgrip weakness were alive five years later compared with 40 per cent of those who had normal handgrip.
The President of ESTRO Yolande Lievens MD PhD, head of the department of radiation oncology at Ghent University Hospital in Belgium, comments about the study findings.
BARCELONA—Accelerated partial breast irradiation (ABPI) brachytherapy completed in a single week gave at least as good efficacy and safety as other radiotherapy protocols after breast-conserving therapy (BCS) for patients with low-risk breast cancer and brought advantages in terms of symptoms and convenience in a randomized phase three trial(conducted at 16 European medical centers)reported at the 2018 European Society for Radiotherapy & Oncology (ESTRO 37) conference. (OC-0326 QOL After APBI (Multicatheter Brachytherapy) Versus WBI: 5-Year Results, Phase 3 GEC-ESTRO Trial)
“We really have to consider further reducing treatment burden for patients with low-risk breast cancer,” said radiation oncologist Philip Poortmans MD PhD, past ESTRO president, Marie Curie Professor and head of department at Paris Science & Lettres, Institut Curie in Paris commenting on the study findings. “And an excellent approach to this is accelerated partial breast irradiation—for which brachytherapy is an excellent solution,”
First author Rebekka Schäfer MD, Resident Medical Doctor at Würzburg University Hospital in Würzburg, Germany talks with the Audio Journal of Oncology about her study in which APBI with brachytherapy was compared directly to whole breast irradiation in the study and was not inferior in terms of overall survival and local recurrence at five years.
Yolande Lievens MD PhD, head of the department of radiation oncology at Ghent University Hospital in Belgium, said the findings endorsed brachytherapy as an option which improved opportunities for individualizing therapy and limiting the volume of the breast being irradiated.
BARCELONA—Image-guided adaptive brachytherapy (IGABT) for patients with cervical cancer did not increase risk for ureteral stricture (a rare but feared complication of pelvic radiotherapy) in European research reported at the European Society for Radiotherapy & Oncology (ESTRO 37) 2018 conference.
(OC-0072 Risk factors for ureteral stricture after IGABT in cervical cancer: results from the EMBRACE studies)
“Our findings show that the risks for severe to life-threatening ureteral strictures are very low in all the patients with limited stage disease,” said first author Lars Fokdal MD PhD, a clinical oncologist from Aarhus University Hospital in Denmark, who told the Audio Journal of Oncology about his group’s updated population-based findings and conclusions from analysis of data from 1772 patients treated with brachytherapy for their locally advanced cervical cancer (LACC) in the retrospective RetroEMBRACE study (with 610 patients) and the prospective EMBRACE (with 1162 patients).
BARCELONA—It is essential to conduct a comprehensive geriatric assessment of patients over 74 with lung cancer before deciding to escalate treatment dose by switching to concurrent chemo-radiotherapy in an attempt to improve outcomes. This was the conclusion of a phase 2 study reported at the European Society for Radiotherapy & Oncology (ESTRO 37) conference.
(PV-0039 Outcome of elderly NSCLC patients treated with isotoxic RT dose-escalation using IMRT—NCT01166204)
Principal investigator Judith van Loon MD PhD, a radiation oncologist at MAASTRO Clinic in Maastricht, The Netherlands told the Audio Journal of Oncology that clinicians could do more harm than good with this treatment if they did not take into account other factors, and that this held true despite the fact that only patients who had excellent performance status were selected for such escalation.180519 van Loon AJO INTERVIEW Production MASTER
BARCELONA—The accuracy of radiation targeting using image-guided radiotherapy (IGRT) was significantly associated with overall survival in a study of a large cohort of patients treated with IGRT for their lung and esophageal cancers. reported at the 2018 European Society For Radiotherapy and Oncology (ESTRO 37) annual conference (ABSTRACT OC-0322, “Residual setup errors after IGRT are linked to overall survival in lung and oesophageal cancers”)
The key hazard was found to be unintended irradiation of the heart. Patients who had residual set-up errors which moved their hearts closer to the high-dose region had significantly worse overall survival compared to those who had a residual shifts away from the heart said first author Corinne Johnson MSc, a physics PhD student at Christie NHS Foundation Trust, University of Manchester and Manchester Cancer Research Centre in the UK in conversation with the Audio Journal of Oncology.Corinne Johnson AJO Production MASTER
© 2009 - 2018 Ebling Library, UW-Madison
750 Highland Ave, Madison, WI, 53705-2221